Get notified of page updates

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.

How to Use Our Search and Enroll Tool

Search Results: Treatment + Endometrial Cancer (7 results)

Printer Friendly Page 1 through 7 of 7
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.

Clinicaltrials.gov identifier: NCT05572684
More info
A Study of  Targeted Therapies for Patients With Recurrent Endometrial Cancer

Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.

 

Clinicaltrials.gov identifier: NCT04486352
More info
Testing an Immunotherapy in Patients with Advanced Solid Tumors

Treatment
Treatment study for people with advanced cancers

Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.

Clinicaltrials.gov identifier: NCT02628067
More info
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

Treatment
Cancer treatment study for people with advanced solid tumors

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Clinicaltrials.gov identifier: NCT02693535
More info
Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

Treatment
Treatment study for people with endometrial cancer that has returned

Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.

Clinicaltrials.gov identifier: NCT05112601
More info
Retifanlimab Alone or with Other Agents for Advanced Endometrial Cancer that Progressed with Platinum

Treatment
Advanced endometrial cancer

Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)

This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.

Clinicaltrials.gov identifier: NCT04463771
More info
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

Clinicaltrials.gov identifier: NCT03607890
More info
Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
100 results
Clinical Trial Official Title
NCT04386993 De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT04683653 Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT05139368 Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT04458402 Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT03932409 Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT05603910 Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT03955978 TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT04570553 Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT04839614 Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT04586959 Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT03785288 Vaginal Cuff Brachytherapy Fractionation Study
NCT05819892 Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT04514692 Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT04527900 The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT06253494 Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT00924027 A Study of Patients Receiving High-Dose Rate Brachytherapy
NCT04567771 Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT06129604 Pilot Window of Opportunity Trial (POET)
NCT05990426 Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT05691010 A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT03422198 Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT03876860 An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
NCT03968406 Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT04997096 Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT05712668 Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT06276491 Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors
NCT05761951 Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT06132958 Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT05591131 Genetic Testing in African Americans
NCT05798611 Study of ART0380 in Patients With Biologically Selected Solid Tumors
NCT05542407 ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05646316 Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT05036681 A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT04576104 Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT05559879 Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT05112601 Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT06218914 A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
NCT06036836 Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT05263492 Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NCT06242470 A Study of MGC026 in Participants With Advanced Solid Tumors
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT04512144 Mindfulness in Endometrial and Cervical Cancer
NCT05039801 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT03835819 A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT05554328 Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05489211 Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05154487 A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT05032040 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04469764 Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT05092373 Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT05538897 Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT06299163 NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
NCT05523440 Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT03675893 Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer
NCT04851119 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04704661 Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT05691504 Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT06172478 A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT04590326 A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
NCT03564340 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT04486352 A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT05768139 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT04080284 Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT05997017 Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05156268 A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
NCT05705505 Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
NCT05655598 TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT05277051 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT03746431 A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT02922764 A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT05564377 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT03682289 Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT03065062 Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT04196257 BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04044859 ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT05150691 A Study of DB-1303 in Advanced/Metastatic Solid Tumors
NCT04104776 A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT04925284 Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT06270706 A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT05827614 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications
NCT05252416 (VELA) Study of BLU-222 in Advanced Solid Tumors
NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT04319757 ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT05086692 A Beta-only IL-2 ImmunoTherapY Study
NCT05500508 Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT04008797 A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
NCT05592626 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05548296 A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT04300556 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Research Search Tool Sponsored By: